On Tuesday Johnson & Johnson (JNJ) reported disappointing third-quarter profits, which slipped more than 6% from one year ago. The company blamed generic competition on several key drugs of theirs, as well as increased spending on marketing new drugs.
“Bottom line” net income dropped to $3.2 billion, or $1.15 a share, from $3.42 billion, or $1.23, a year earlier, reports Bloomberg.
Johnson & Johnson is currently facing generic competition on its antibiotic Levaquin and its attention deficit disorder medication Concerta, which together had generated almost 5% of revenue last year.
On a brighter note, J&J raised its lower-end forecast for 2011 profit, and its earnings adjusted for one-time items beat analyst expectations.
The generic competitors cost J&J “a few hundred million in sales,” said Jeff Jonas, a Gabelli & Co. analyst in an interview with Bloomberg before the company’s announcement. “And they’re still investing pretty heavily to launch their new drugs.”
This disappointing earnings report may make you question whether other drugmakers will meet the same fate. After all, generic competition is affecting virtually all major drugmakers in some way today.
For a look at other major drugmakers yet to report their third-quarter earnings, here is a list of four drugmakers soon to report:
1. Abbott Laboratories (ABT, Earnings, Analysts, Financials): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Market cap of $81.63B. Earnings to be released on 10/19. Among 17 analysts surveyed, the average EPS estimate for this quarter is $1.17 vs. year-ago EPS at $1.05.
2. Eli Lilly & Co. (LLY, Earnings, Analysts, Financials): Develops, manufactures, and sells pharmaceutical products worldwide. Market cap of $44.56B. Earnings to be released on 10/20. Among 16 analysts surveyed, the average EPS estimate for this quarter is $1.12 vs. year-ago EPS at $1.21
3. Bristol-Myers Squibb Company (BMY, Earnings, Analysts, Financials): Develops, and delivers innovative medicines that help patients prevail over serious diseases. Market cap of $55.54B. Earnings to be released on 10/27. Among 17 analysts surveyed, the average EPS estimate for this quarter is $0.57 vs. year-ago EPS at $0.59.
4. Merck & Co. Inc. (MRK, Earnings, Analysts, Financials): Provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. Market cap of $101.02B. Earnings to be released on 10/28. Among 18 analysts surveyed, the average EPS estimate for this quarter is $0.90 vs. year-ago EPS at $0.8
(Written by Alexander Crawford. EPS estimates sourced from Yahoo! Finance, data sourced from Finviz.)
Use Kapitall’s Tools: Looking for ways to analyze this list?
Use this article snapshot as a launch pad (click here for help): Simply click on the links, and use Kapitall’s tab navigation to browse through the data…
Analyze These Ideas: Getting Started
- Read descriptions for all companies mentioned
- Access a performance overview for all stocks in the list
- Compare analyst ratings for the companies mentioned
- Compare analyst ratings to annual returns for stocks mentioned
- Real-Time Opinion: Scan the latest tweets about these companies (feed will open in a new window)
Dig Deeper: Access Company Snapshots, Charts, Filings
- Abbott Laboratories (ABT, Chart, Download SEC Filings)
- Eli Lilly & Co. (LLY, Chart, Download SEC Filings)
- Bristol-Myers Squibb Company (BMY, Chart, Download SEC Filings)
- Merck & Co. Inc. (MRK, Chart, Download SEC Filings)
New to Kapitall?
1. New to the site? Click here to register for a free account, and gain access to more tools and data
2. Looking for more investing ideas like this? Click here to sign up for your free copy of Kapitall Weekly
3. Follow us on SeekingAlpha, Motley Fool, Nasdaq and Twitter